Clinical Efficacy and Safety of Topical Roflumilast in Psoriasis: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Adnan Khattak(Edith Cowan University), Bibek Shrestha(Tribhuvan University), Muhid Khattak(Lady Reading Hospital), Farman Ullah Khan(Ayub Medical College), Abdul Moiz Khan(Ayub Medical College), Rumaisa Riaz(Dow University of Health Sciences), Zeeshan Imtiaz(Mayo Hospital), A Roy(Barking, Havering And Redbridge University Hospitals NHS Trust), Ummi Aiman Rahman(King Edward Medical University), Hassan Mirza(Sultan Qaboos University), Fatima Javid(Women Medical College), Ahmed Javed(Ayub Medical College)
Cited by 0
Related Papers
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
|JAMA Oncology|2020|439